Home / Bioanalytical and biomarker services / Preclinical services / In vitro
In Vitro CRO Services
Comprehensive cell-based testing, in vitro assay development and efficacy studies designed to de-risk your rare disease program before human trials.
Robust data for early decision-making
As an experienced in vitro CRO, we conduct rigorous in vitro testing to evaluate critical safety and efficacy signals early in development. Our senior scientists help you establish the exact context of use to ensure your cell-based data provides a reliable foundation for downstream clinical execution.
Comprehensive cell-based evaluations
We apply proven methods to characterize myogenic cultures and evaluate specific biomarker responses for your therapeutic candidate.
Activity screening and cytotoxicity
We perform detailed screening to evaluate drug activity and assess cellular toxicity before your program advances to in vivo models.
Biochemical and molecular outcomes
We use advanced techniques like digital droplet PCR and Western blotting to accurately measure gene expression and target proteins.
Muscle physiology testing
We assess functional metrics, including fatigue resistance and specific force, to quantify therapeutic impact at the cellular level.
Discuss your in vitro study design
Engage our senior scientists to establish a rigorous in vitro testing plan for your rare disease program.
Specialized expertise in rare disease research
AGADA Biosciences applies focused scientific rigor to evaluate subtle therapeutic signals. We leverage decades of established research to identify operational challenges early and ensure your data withstands regulatory scrutiny.
Myogenic culture specialization:
We provide targeted in vitro testing, including immunocytochemistry and fusion index analysis, to map cellular responses.
Harmonized workflows:
We align our early discovery standard operating procedures with clinical protocols to drastically reduce downstream technology transfer time.
Direct scientist access:
Our lean model ensures you work directly with the senior experts, guiding your study design and interpreting your biomarker data.
Early risk identification:
We proactively address scientific challenges during early testing to ensure readiness for first-in-human trials.
Predictable schedules for early testing
We design pilot studies and comprehensive evaluations that maximize your resources and keep your program on track.
Built to integrate
AGADA Biosciences acts as a collaborative partner that integrates smoothly into your existing vendor ecosystem. We manage specialized workflows without demanding total control of your rare disease program.
A continuous path to clinical execution
Keeping your early efficacy studies and clinical bioassays under one roof provides consistency and gives your therapy the best chance of first-time success.
Context of use alignment:
We help define the exact regulatory context early so your cell-based endpoints remain strictly fit for purpose.
Protein expression analysis:
We utilize established methods to accurately map target protein localization and intensity across your cell cultures.
Regulatory readiness:
We operate in compliance with GLP guidelines to ensure your early research yields data regulators can trust.
Smooth transitions:
We eliminate silos between early research and clinical execution to prevent costly handoffs and protect data integrity.
Start a conversation
Reach out to our team to ensure your in vitro data is reliable and ready for the next stage of development.
Where history meets innovation
In the heart of downtown Halifax, AGADA has transformed a historic building into a modern facility dedicated to advancing rare disease therapeutics. Take a closer look at our laboratories, scientific capabilities and dedicated team and discover how our unique location and collaborative environment support the work we do for clients and patients worldwide.
Quality and compliance
We operate in strict compliance with GCP, GLP and GDPR regulations to ensure your data remains interpretable and defensible. Every team member must hold a CITI certification before supporting any sponsor trial.
Meet our scientific leadership
Our founders and senior scientists are globally recognized leaders in rare and neuromuscular disease research, bringing decades of specialized expertise to your program.
News and resources
AGADA Biosciences executes rigorous in vitro testing to evaluate critical biomarkers and de-risk your transition into human clinical trials.
